Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Wix.Com Ltd (WIX) Price & Performance

Wix.Com LtdTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Wix.Com Ltd — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: Sanofi SA is far larger — about 30.6× Wix.Com Ltd's market cap, and Sanofi SA pays a 6.01% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Wix.Com Ltd for 62 Days on average.

SNYWIX
Market Cap
$95.18B$3.11B
Volume
2,995,646809,286
Sector
HealthTechnology
52-Week High
$52.34$145.54
52-Week Low
$39.51$40.43
Typical Hold Time
94 Days62 Days
Enterprise Value
$114.48B$4.19B
Dividend Yield
6.01%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.

While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.

Wix.Com Ltd

WIX stock trades at $74.13, up 1.59% today, with a neutral technical signal and bullish moving averages. Revenue grew to $1.99B in 2025, but net income margin is negative at -8.19%. The company faces a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026. Analyst consensus is a Buy with a $77.00 price target, though valuation ratios like P/E of 62.84 appear elevated.

The outlook is mixed: strong revenue growth and positive cash flow from operations support the bullish analyst stance, but legal risks and negative profitability margins pose significant headwinds. Upside depends on sustained earnings beats and resolution of litigation, while downside risks include prolonged negative margins and competitive pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SNY
35% Buy65% Sell
Avg holding period · 94 Days
WIX
0% Buy100% Sell
Avg holding period · 62 Days

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →

About Wix.Com Ltd

Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.

Read more on WIX →